This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

The Effect of Antipsychotic Treatment on Recurrent Venous Thromboembolic Disease: A Cohort Study

Augusto Ferraris, MD; Alejandro G. Szmulewicz, MD, MPH; M. Lourdes Posadas-Martínez, MD, MSc, PhD; Marina Alonso Serena, MD; Fernando J. Vazquez, MD, PhD; and Federico Angriman, MD, MPH Augusto Ferraris, MDa,b,*; Alejandro G. Szmulewicz, MD, MPHb,c; M. Lourdes Posadas-Martínez, MD, MSc, PhDa; Marina Alonso Serena, MDa; Fernando J. Vazquez, MD, PhDa; and Federico Angriman, MD, MPHd,e

Published: August 27, 2019

Article Abstract

Background: Venous thromboembolism (VTE) represents a major cause of morbidity and mortality worldwide. Antipsychotic treatment is associated with an increased risk of thromboembolic disease, an effect that seems to be constant across the spectrum of distinct agents. This study sought to delineate the effect of new antipsychotic use on the risk of recurrent thromboembolic events after a first episode of either deep venous thrombosis or pulmonary embolism.

Methods: This cohort study, conducted between January 2010 and June 2017, was based on a prospectively collected database of adult patients with VTE. The main exposure was the new onset of antipsychotic treatment after having a first episode of venous thromboembolic disease. The primary outcome was defined as recurrent VTE, either deep venous thrombosis or pulmonary embolism, during long-term follow-up. The composite of all-cause mortality and recurrent VTE served as the secondary outcome. An inverse probability weighted multivariable Cox proportional hazards model was fitted to adjust for measured confounding and competing risks.

Results: One thousand one hundred three patients were included in the present analysis, of whom 136 were identified as new users of antipsychotic agents. A total of 67% of patients were currently treated with full-dose anticoagulation at baseline. No association was found between the new use of antipsychotic agents and recurrent VTE during follow-up (adjusted hazard ratio (HR) = 1.08; 95% CI, 0.38-3.08). However, the use of these agents was associated with a 63% increased risk of recurrent VTE or all-cause mortality (adjusted HR = 1.63; 95% CI, 1.26-2.10).

Conclusions: The use of antipsychotic agents among patients with a first episode of VTE and full-dose anticoagulation was not associated with an increased risk of recurrent thromboembolic events. However, antipsychotic treatment was associated with a higher risk of both VTE and all-cause mortality. Further studies are warranted to confirm these findings.

Volume: 80

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF